Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.93−0.08 (-3.98%)
Close on Nov 11, 2026Market cap $3.15MP/E –Yield –
Ernexa Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Ernexa Therapeutics's gross margin for the twelve months ending Dec 31, 2024 was 83.5%. For fiscal 2024 it was 83.5%, against -247.1% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 83.5% | +330.6 |
| FY2023 | Dec 31, 2023 | -247.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | 100.0% | +388.2 |
| Q3 FY2024 | Sep 30, 2024 | 112.3% | +247.6 |
| Q2 FY2024 | Jun 30, 2024 | -102.1% | – |
| Q1 FY2024 | Mar 31, 2024 | -29.8% | – |
| Q4 FY2023 | Dec 31, 2023 | -288.2% | – |
| Q3 FY2023 | Sep 30, 2023 | -135.3% | – |
See a number that looks wrong?